Groundbreaking Drug Launches
Sibeprenlimab (VOYXACT)
Mechanism of Action: Tumour necrosis factor ligand superfamily member 13 inhibitors Drug class: Monoclonal antibodies Originator: Visterra Indication: IgA nephropathy
Launched date: December 2025 (USA) Trials: VISIONARY
IgA nephropathy
IgA nephropathy, also called Berger disease, is a kidney disorder in which immunoglobulin A (IgA)—a protein that helps the body fight infections—accumulates in the kidneys. This buildup triggers inflammation that gradually damages the kidneys and reduces their ability to filter waste from the blood.
The disease typically progresses slowly over many years, but its severity and course differ widely among individuals. Some people may have blood in their urine with no other symptoms, while others experience complications such as protein leakage in the urine and declining kidney function. In more severe cases, IgA nephropathy can progress to kidney failure, where the kidneys can no longer adequately remove waste from the body.
Treatment challenges Treatment of IgA nephropathy is challenging due to its highly variable course, lack of curative therapies, and difficulty predicting disease progression or treatment response. Management relies largely on supportive care, such as controlling blood pressure and proteinuria, while balancing the side effects of immunosuppressants and making age-specific treatment decisions. The slow, heterogeneous nature of the disease also complicates clinical trial design, underscoring the need for better biomarkers and more targeted therapies.
Why is Sibeprenlimab poised to make an impact in 2026?
Sibeprenlimab (Voyxact) is a monoclonal IgG2 antibody targeting the B-cell growth factor APRIL (TNFSF13), developed by Visterra, a subsidiary of Otsuka America Pharmaceutical, for the treatment of immunoglobulin A (IgA) nephropathy and Sjögren syndrome. Voyxact is expected to be a key therapy for IgA nephropathy in 2026, with early-2026 VISIONARY trial data anticipated to confirm its ability to slow the decline in kidney function. Building on its recent accelerated approval for reducing proteinuria, positive long-term data could support full FDA approval and solidify its role as a leading treatment. By targeting APRIL, Voyxact offers a novel, disease-focused approach, though its ultimate impact depends on sustained kidney outcomes. While Otsuka has not disclosed revenue projections, analysts estimate the IgAN market could reach $6–10 billion annually.
Regulatory milestones for Sibeprenlimab
Registrational Trial
The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. VOYXACT was granted accelerated approval based on the VISIONARY Phase 3 interim analysis.
VISIONARY:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy (NCT05248646).
“The VISIONARY trial results underscore sibeprenlimab’s potential to meaningfully alter the course of IgA nephropathy, demonstrating promising effects on proteinuria and kidney protection that support its role as a targeted, disease-modifying therapy.”